Embecta Corp.
Health
Performance
8.9
Risk
Sell
Buy
Curious about the Scores? Learn more.

Embecta Corp. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

03.01.2026
Red alert. Risk levels out of control.
26.11.2025
Breaking down. The red game over screen is flashing.
25.11.2025
Momentum tanked. Clearly underperforming.
20.08.2025
Climbing out. Risks fading, but not out of the woods.
EMBC
Embecta Corp.
3.25
-3.56%
8.9
Sell
Buy
Embecta Corp.

Embecta Corp. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Embecta Corp. do? Business model and key facts

Get the full picture of Embecta Corp.: what it builds, where it operates, and how it makes money.

Embecta Corp. Profile

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees (FY): 1850

Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.

shop
Company facts
Devdatt Kurdikar
CEO
1850
Employees worldwide
shop
Performance
-69.6%
Last 12 months
-93.09%
Last 5 years
shop
Growth
$1.08B
Revenue year
$95.40M
Net income
shop
Valuation
$192.81M
Market Cap
8.60
Price/Earnings Ratio

Stocks related to Embecta Corp.

Selected based on industry alignment and relative market positioning.

SIGA
SIGA Technologies, Inc.
3.39
-5.31%
8.6
Sell
Buy
SIGA Technologies, Inc.
SNDL
SNDL Inc.
1.27
-1.55%
7.1
Sell
Buy
SNDL Inc.
ORGO
Organogenesis Holdings Inc.
2.47
-7.84%
7.8
Sell
Buy
Organogenesis Holdings Inc.
LFCR
Lifecore Biomedical, Inc.
4.58
-1.29%
9.0
Sell
Buy
Lifecore Biomedical, Inc.
OGI
Organigram Global Inc.
0.92
-2.91%
10.0
Sell
Buy
Organigram Global Inc.

Events and news impacting Embecta Corp. stock

Earnings, coporate decisions and industry developments that can affect the share price.

Embecta Corp. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.